Nano Retina

Artificial Retina

Health Tech & Life Sciences
Non Active, Aug 2023 ceased to operate

Company Overview

Snapshot

Founded in January 2009, Nano Retina operated with 11–50 employees, developing an artificial retina solution. The company raised $750K across one funding round. In August 2023, Nano Retina ceased operations.

Business overview

Nano Retina developed a solution aimed at restoring sight for individuals with retinal degenerative diseases. Its core product, the NR600 Implant, is a miniature device designed to replace damaged photoreceptor cells and stimulate healthy retinal cells. The company's technology involves a minimally invasive surgical procedure for implanting the chip, which integrates all necessary functionalities without external wiring. Nano Retina operated within the Health Tech & Life Sciences sector, focusing on medical devices and treatments for visually impaired patients.

Strategic signal

Nano Retina ceased operations in August 2023. This indicates a significant strategic shift, as the company is no longer actively pursuing its mission to develop and commercialize its artificial retina technology. For investors, this signals the discontinuation of the company's product development and market entry efforts.

Company Intelligence Q&A

What is Nano Retina's primary focus?
Nano Retina focuses on developing an artificial retina solution to restore sight for individuals who have lost their vision due to retinal degenerative diseases.
When was Nano Retina founded?
Nano Retina was founded in January 2009.
What is the NR600 Implant?
The NR600 Implant is Nano Retina's miniature device designed to replace the functionality of damaged photoreceptor cells and electrically stimulate remaining healthy retinal cells, aiming to restore vision.
What was the last reported status of Nano Retina?
Nano Retina ceased to operate in August 2023.
What was the total disclosed capital raised by Nano Retina?
Nano Retina raised a total of $750K across one funding round.

External links